MED(MED)
MED
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $280M | $256M |
| Low | $280M | $256M |
| High | $280M | $256M |
| EBITDA Avg | $25M | $23M |
| Low | $25M | $23M |
| High | $25M | $23M |
| EBIT Avg | $21M | $19M |
| Low | $21M | $19M |
| High | $21M | $19M |
| Net Income Avg | $-20M | $-7M |
| Low | $-20M | $-7M |
| High | $-20M | $-7M |
| EPS Avg | $-1.85 | $-0.60 |
| Low | $-1.85 | $-0.60 |
| High | $-1.85 | $-0.60 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $68M | $63M | $66M | $65M | $63M | $61M |
| Low | $68M | $63M | $66M | $65M | $63M | $61M |
| High | $68M | $63M | $66M | $65M | $63M | $61M |
| EBITDA Avg | $6M | $6M | $6M | $6M | $6M | $5M |
| Low | $6M | $6M | $6M | $6M | $6M | $5M |
| High | $6M | $6M | $6M | $6M | $6M | $5M |
| EBIT Avg | $5M | $5M | $5M | $5M | $5M | $5M |
| Low | $5M | $5M | $5M | $5M | $5M | $5M |
| High | $5M | $5M | $5M | $5M | $5M | $5M |
| Net Income Avg | $-7M | $-2M | $-3M | $-2M | $-1M | $-1M |
| Low | $-7M | $-2M | $-3M | $-2M | $-1M | $-1M |
| High | $-7M | $-2M | $-3M | $-2M | $-1M | $-1M |
| EPS Avg | $-0.62 | $-0.18 | $-0.24 | $-0.15 | $-0.10 | $-0.11 |
| Low | $-0.62 | $-0.18 | $-0.24 | $-0.15 | $-0.10 | $-0.11 |
| High | $-0.62 | $-0.18 | $-0.24 | $-0.15 | $-0.10 | $-0.11 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |